Debiopharm obtains global rights from Novo Nordisk for the development of their ubiquitin-specific protease 1 (USP1) inhibitor LAUSANNE, Switzerland, March…
Facilitated 40% increase in Credit Approval Ratio with improved strength in collectionsDelivered 20% reduction in Net Credit Loss with digitizationPowered…